More FDA inspection troubles for Hospira

June 7, 2013 by Sony Salzman

The FDA says Hospira’s India facility is still rife with significant violations of good manufacturing practice regulations.

http://www.massdevice.com/sites/default/files/logos/hospira-logo-2x2.jpg

Hospira (NYSE:HSP) heard from the FDA's inspection office this week with another warning that the infusion device company's India facility still contains significant violations of good manufacturing practice regulations.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Comments

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp